PEAK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4192433	0.55	1/20
SCHEMBL29230284	0.53	1/20
SCHEMBL4245389	0.52	1/20
SCHEMBL17516462	0.52	1/20
SCHEMBL30945075	0.52	1/20
SCHEMBL28322311	0.51	1/20
SCHEMBL14276917	0.49	1/20
SCHEMBL38661156	0.49	1/20
SCHEMBL4251960	0.48	1/20
SCHEMBL5107750	0.46	1/20
SCHEMBL8276000	0.46	1/20
SCHEMBL28322310	0.46	1/20
SCHEMBL17080821	0.45	1/20
SCHEMBL4188823	0.44	1/20
SCHEMBL8222723	0.44	1/20
SCHEMBL38660366	0.43	1/20
SCHEMBL390513	0.43	1/20
SCHEMBL4184815	0.43	1/20
SCHEMBL29230289	0.43	1/20
SCHEMBL6334518	0.42	1/20

Clinical trials — most relevant to PEAK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Brain Function and Structure in Cocaine Dependence	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes	PHASE2	COMPLETED
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes	PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment	PHASE1	COMPLETED
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans	PHASE1	COMPLETED
Imaging the Neurochemistry of Drug Addiction With PET	EARLY_PHASE1	COMPLETED
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo	nan	UNKNOWN
Heart Failure and a Preserved Ejection Fraction	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Transcranial Magnetic Stimulation for Children With Tourette's Syndrome	nan	COMPLETED
Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.	nan	COMPLETED
Use of miRNAs in Growth Hormone Deficiency (GHD)	nan	UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Magnetic Resonance Elastography (MRE) of Uterine Fibroids	nan	COMPLETED
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)	nan	WITHDRAWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Neurofeedback in Clinical High Risk	nan	NOT_YET_RECRUITING
A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.	nan	RECRUITING
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PEAK1 binder may also engage these)

Protein	Name	Similarity
Q69Z38	—	1.000	Q69Z38 →
Q498L0	—	1.000	Q498L0 →
A2RUV4	—	1.000	A2RUV4 →
Q0KIC3	—	1.000	Q0KIC3 →
Q8IZ21	—	0.999	Q8IZ21 →
Q8IVL0	—	0.998	Q8IVL0 →
Q949U2	—	0.998	Q949U2 →
O14490	—	0.998	O14490 →
A0A1S4GMU2	—	0.998	A0A1S4GMU2 →
Q9D415	—	0.997	Q9D415 →
O94875	—	0.997	O94875 →
Q9UJM3	—	0.997	Q9UJM3 →
A2ARZ3	—	0.997	A2ARZ3 →
Q6YXZ4	—	0.996	Q6YXZ4 →
Q9UHV7	—	0.996	Q9UHV7 →
Q3ZBS1	—	0.996	Q3ZBS1 →
Q95QY7	—	0.996	Q95QY7 →
G5EEC5	—	0.996	G5EEC5 →
P21999	—	0.996	P21999 →
Q8NB66	—	0.996	Q8NB66 →
Q52KW0	—	0.996	Q52KW0 →
Q05935	—	0.996	Q05935 →
SORBS1	Sorbin and SH3 domain-containing protein 1	0.996	landscape →
P97839	—	0.996	P97839 →
Q9N1U3	—	0.996	Q9N1U3 →
Q9SB51	—	0.995	Q9SB51 →
Q62770	—	0.995	Q62770 →
Q62417	—	0.995	Q62417 →
Q9UPX6	—	0.995	Q9UPX6 →
Q9SR66	—	0.995	Q9SR66 →